Table 2. Loss of Response and Achievement of EASI 75 at Week 52 by Week 16 Response Status (ITT Population).
| UPA 15 mg | UPA 30 mg | |||
|---|---|---|---|---|
| No.a | No. (%) [95% CI] | No.a | No. (%) [95% CI] | |
| Proportion of patients who experienced loss of response after wk 16 up to wk 52 among wk-16 EASI 75 and vIGA-AD 0/1 responders a , b | ||||
| Measure Up 1 | ||||
| Overallc | 133 | 4 (3.0) [0.1-5.9] | 176 | 6 (3.4) [0.7-6.1] |
| Week 20 | 131 | 0 | 170 | 2 (1.2) [0-2.8] |
| Week 24 | 120 | 0 | 166 | 1 (0.6) [0-1.8] |
| Week 32 | 126 | 4 (3.2) [0.1-6.2] | 160 | 1 (0.6) [0-1.8] |
| Week 40 | 120 | 1 (0.8) [0-2.5] | 159 | 1 (0.6) [0-1.9] |
| Week 52 | 121 | 0 | 161 | 2 (1.2) [0-3.0] |
| Measure Up 2 | ||||
| Overallc | 107 | 6 (5.6) [1.2-10.0] | 142 | 7 (4.9) [1.4-8.5] |
| Week 20 | 106 | 0 | 139 | 0 |
| Week 24 | 102 | 2 (2.0) [0-4.7] | 139 | 3 (2.2) [0-4.6] |
| Week 32 | 102 | 2 (2.0) [0-4.7] | 135 | 1 (0.7) [0-2.2] |
| Week 40 | 101 | 0 | 133 | 2 (1.5) [0-3.6] |
| Week 52 | 100 | 3 (3.0) [0-6.3] | 129 | 4 (3.1) [0.1-6.1] |
| Proportion of patients achieving EASI 75 at wk 52 among wk-16 EASI 75 responders d | ||||
| Measure Up 1 | 175 | 153 (87.4) [82.5-92.3] | 207 | 183 (88.4) [84.0-92.8] |
| Measure Up 2 | 157 | 137 (87.3) [82.0-92.5] | 189 | 172 (91.0) [86.9-95.1] |
| Integrated population | 332 | 290 (87.3) [83.8-90.9] | 396 | 355 (89.6) [86.6-92.6] |
| Proportion of patients achieving EASI 75 at wk 52 among wk-16 EASI 75 nonresponders e | ||||
| Measure Up 1 | 57 | 37 (64.9) [52.5-77.3] | 24 | 14 (58.3) [38.6-78.1] |
| Measure Up 2 | 73 | 45 (61.6) [50.5-72.8] | 35 | 16 (45.7) [29.2-62.2] |
| Integrated population | 130 | 82 (63.1) [54.8-71.4] | 59 | 30 (50.8) [38.1-63.6] |
Abbreviations: EASI 75, 75% or greater improvement in Eczema Area and Severity Index; ITT, intention to treat for the main study; UPA, upadacitinib; vIGA-AD 0/1, Validated Investigator Global Assessment for Atopic Dermatitis of clear (0) or almost clear (1) with 2 or more grades of reduction.
a
Loss of response was defined as loss of 50% or greater of the week-16 EASI response and vIGA-AD 2 or greater after week 16.
b
Responders were defined as patients who achieved EASI 75 and vIGA-AD 0/1 at week 16.
c
At any time between week 16 up to week 52.
d
Responders were defined as patients who achieved EASI 75 at week 16.
e
Nonresponders were defined as patients who did not achieve EASI 75 at week 16.